Celldex Therapeutics is developing Rintega, a treatment for glioblastoma, and results presented at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) showed a significant increase in long-term overall survival for patients who participated in Rintega's phase 2 trials.
ABC2 funded this research in the early stages. "This is the vaccine developed by Drs. John Sampson and Duane Mitchell at Duke for the 30% of patients with an EGFRvIII mutation in their brain tumors ," said Max Wallace, CEO of ABC2. "Certainly not a cure, but positive news regarding the potential for immune therapy. Our goal right now is to add months for patients with the hope that, as science progresses, those months can grow to years."
Click here for an update on Rintega by Luke Timmerman in Forbes.